A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

New intellectual property enables Cascade LF product line to deliver even higher performance and lower cost, strengthening leadership in RNG innovation~ VANCOUVER, BC , Oct. /CNW/ ...

Learn more about prostate cancer and why there is a debate over whether or not patients should get tested for it.

Stellantis says it will invest $13 billion over the next four years to expand its manufacturing capacity in the United States ...

Protecting your prostate health involves proactive lifestyle choices. Experts recommend a plant-based, high-fibre diet rich ...

Infineon Technologies is expanding its Edge AI portfolio with the DEEPCRAFT AI Suite – a comprehensive set of software & tools ...

A new virus, Brt_Psa3, shows promise against bacterial canker, a major kiwifruit disease. Isolated from a Portuguese orchard, it effectively reduces harmful bacteria on leaves.

(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...

Disease activity and multimorbidity among patients in the US with PsA varied based on geographic region, socioeconomic deprivation, race, and gender.

Scientists based in Australia and China have identified a pair of pesky enzymes responsible for prolonging prostate cancer – ...

Experts date the beginning of the tech boom to somewhere in the 1990s. We've been living with microchips, laptops, and ...